Maurer, M., Berger, W., Giménez Arnau, A. M., Hayama, K., Jain, V., Reich, A., . . . Storim, J. (2022). Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria.
Citación estilo ChicagoMaurer, Marcus, et al. Remibrutinib, a Novel BTK Inhibitor, Demonstrates Promising Efficacy and Safety in Chronic Spontaneous Urticaria. 2022.
Cita MLAMaurer, Marcus, et al. Remibrutinib, a Novel BTK Inhibitor, Demonstrates Promising Efficacy and Safety in Chronic Spontaneous Urticaria. 2022.
Precaución: Estas citas no son 100% exactas.